Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease

被引:79
|
作者
Lindahl, Gisela E. [1 ,2 ]
Stock, Carmel J. W. [1 ,2 ]
Xu Shi-Wen [3 ]
Leoni, Patricia [1 ,2 ]
Sestini, Piersante [4 ]
Howat, Sarah L. [5 ]
Bou-Gharios, George [6 ]
Nicholson, Andrew G. [7 ,8 ]
Denton, Christopher P. [3 ]
Grutters, Jan C. [9 ,10 ]
Maher, Toby M. [1 ,2 ]
Wells, Athol U. [1 ,2 ]
Abraham, David J. [3 ]
Renzoni, Elisabetta A. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Interstitial Lung Dis Unit, Royal Brompton Hosp, London SW3 6LR, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LR, England
[3] UCL, Sch Med, Ctr Rheumatol & Connect Tissue Dis, London NW3 2PF, England
[4] Univ Siena, Osped Le Scotte, Dept Resp Med, I-53100 Siena, Italy
[5] Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England
[6] Univ Oxford, Kennedy Inst Rheumatol, London W6 8HL, England
[7] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Histopathol, London SW3 6LR, England
[8] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LR, England
[9] St Antonius Hosp Nieuwegein, Ctr Interstitial Lung Dis, Utrecht, Netherlands
[10] Univ Med Ctr Utrecht, Div Heart & Lungs, Utrecht, Netherlands
关键词
SSc-ILD; IPF; Pulmonary fibroblasts; Interferon regulated genes; IDIOPATHIC PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; KEY REGULATOR; EXPRESSION; MYOFIBROBLAST; CELLS; BETA; MICE; INHIBITION; SIGNATURES;
D O I
10.1186/1465-9921-14-80
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Interstitial lung disease is a major cause of morbidity and mortality in systemic sclerosis (SSc), with insufficiently effective treatment options. Progression of pulmonary fibrosis involves expanding populations of fibroblasts, and the accumulation of extracellular matrix proteins. Characterisation of SSc lung fibroblast gene expression profiles underlying the fibrotic cell phenotype could enable a better understanding of the processes leading to the progressive build-up of scar tissue in the lungs. In this study we evaluate the transcriptomes of fibroblasts isolated from SSc lung biopsies at the time of diagnosis, compared with those from control lungs. Methods: We used Affymetrix oligonucleotide microarrays to compare the gene expression profile of pulmonary fibroblasts cultured from 8 patients with pulmonary fibrosis associated with SSc (SSc-ILD), with those from control lung tissue peripheral to resected cancer (n=10). Fibroblast cultures from 3 patients with idiopathic pulmonary fibrosis (IPF) were included as a further comparison. Genes differentially expressed were identified using two separate analysis programs following a set of pre-determined criteria: only genes significant in both analyses were considered. Microarray expression data was verified by qRT-PCR and/or western blot analysis. Results: A total of 843 genes were identified as differentially expressed in pulmonary fibroblasts from SSc-ILD and/or IPF compared to control lung, with a large overlap in the expression profiles of both diseases. We observed increased expression of a TGF-beta response signature including fibrosis associated genes and myofibroblast markers, with marked heterogeneity across samples. Strongly suppressed expression of interferon stimulated genes, including antiviral, chemokine, and MHC class 1 genes, was uniformly observed in fibrotic fibroblasts. This expression profile includes key regulators and mediators of the interferon response, such as STAT1, and CXCL10, and was also independent of disease group. Conclusions: This study identified a strongly suppressed interferon-stimulated gene program in fibroblasts from fibrotic lung. The data suggests that the repressed expression of interferon-stimulated genes may underpin critical aspects of the profibrotic fibroblast phenotype, identifying an area in pulmonary fibrosis that requires further investigation.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
    Yamakawa, Hideaki
    Takemura, Tamiko
    Iwasawa, Tae
    Yamanaka, Yumie
    Ikeda, Satoshi
    Sekine, Akimasa
    Kitamura, Hideya
    Baba, Tomohisa
    Iso, Shinichiro
    Okudela, Koji
    Kuwano, Kazuyoshi
    Ogura, Takashi
    BMC PULMONARY MEDICINE, 2018, 18
  • [22] Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease
    Gerbino, Anthony J.
    Goss, Christopher H.
    Molitor, Jernj A.
    CHEST, 2008, 133 (02) : 455 - 460
  • [23] ROLE OF ENDOPLASMIC RETICULUM STRESS IN THE PATHOGENESIS OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Bogatkevich, G.
    Akter, T.
    Atanelishvili, I.
    Liang, J.
    Spyropoulos, D.
    Silver, R.
    RHEUMATOLOGY, 2012, 51 : 5 - 5
  • [24] Kl-6 As A Predictor Of Progression In Scleroderma-Associated Interstitial Lung Disease
    Watanabe, S.
    Saeki, K.
    Waseda, Y.
    Takato, H.
    Ichikawa, Y.
    Murata, A.
    Hara, J.
    Sone, T.
    Abo, M.
    Kimura, H.
    Yasui, M.
    Kasahara, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease
    Talotta, Rossella
    IMMUNOTHERAPY, 2021, 13 (03) : 241 - 256
  • [26] MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM THE AUSTRALIAN SCLERODERMA COHORT STUDY
    Owen, C.
    Ngian, G.
    Moore, O.
    Stevens, W.
    Proudman, S.
    Roddy, J.
    Zochling, J.
    Nash, P.
    Hill, C.
    Sturgess, A.
    Sahhar, J.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 36 - 36
  • [27] The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease
    Matson, Scott M.
    Lee, Seoyeon J.
    Peterson, Ryan A.
    Achtar-Zadeh, Natalia A.
    Boin, Francesco
    Wolters, Paul J.
    Lee, Joyce S.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (06)
  • [28] Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study.
    Owen, Claire
    Ngian, Gene
    Elford, Kathleen
    Moore, Owen
    Nikpour, Mandy
    Stevens, Wendy
    Proudman, Susanna
    Roddy, Janet
    Zochling, Jane
    Hill, Catherine
    Nash, Peter
    Sturgess, Allan
    Sahhar, Joanne
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S740 - S741
  • [29] THE STABILIZATION OF LUNG FUNCTION IN PATIENTS WITH SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE DURING MYCOPHENOLATE MOFETIL THERAPY
    Koneva, O.
    Ananjeva, L.
    Korzeneva, L.
    Alekperov, R.
    Desinova, O.
    Starovoytova, M.
    Nevskaja, T.
    Ovsjannikova, O.
    RHEUMATOLOGY, 2012, 51 : 84 - 84
  • [30] Cyclophosphamide refractory scleroderma-associated interstitial lung disease: dramatic clinical and radiological response to rituximab
    Haroon, M.
    Ryan, J. G.
    Henry, M.
    Harney, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S173 - S173